Is high flow nasal cannula as an effective oxygen delivery alternative in intensive care unit?

Authors

  • Amrish Patel Department of Pulmonary and Critical Care Medicine, Sterling Hospital, Ahmedabad, Gujrat, India
  • Jitesh Atram Department of Pulmonary and Critical Care Medicine, Sterling Hospital, Ahmedabad, Gujrat, India
  • H. S. Dumra Department of Pulmonary and Critical Care Medicine, Sterling Hospital, Ahmedabad, Gujrat, India
  • Mansi Dandnaik Department of Pulmonary and Critical Care Medicine, Sterling Hospital, Ahmedabad, Gujrat, India
  • Gopal Raval Department of Pulmonary and Critical Care Medicine, Sterling Hospital, Ahmedabad, Gujrat, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20191159

Keywords:

HFNC, Pneumonia, Respiratory failure

Abstract

Background: High-flow nasal cannula (HFNC) oxygen therapy is carried out using an air/oxygen blender, active humidifier, single heated tube, and nasal cannula. It is an oxygen delivery system which uses air blender to deliver accurate oxygen concentration to the patient from 21% to 100% at desired temperature. It can be administered via wide bore nasal cannula or to the tracheostomy tube via connector. It can give upto 60L/min flow hence can generate positive end expiratory pressure between 2 to 7 cmH20. By providing humidified oxygen along with the high flow rates it satisfies air hunger and reduces work of breathing for the patient.

Methods: This is a retrospective observational study. Patients with persistent hypoxia in spite of conventional oxygen therapy were treated with HFNC. Patients with possible need for immediate invasive ventilator support were excluded. Clinical respiratory parameters and oxygenation were compared under conventional and HFNC oxygen therapy.

Results: Thirty patients, aged more than 18 years admitted in intensive respiratory care unit with acute hypoxemic respiratory failure from June 2017 to January 2018 were included in the study. Study period was of 6 months. Etiology of acute respiratory failure (ARF) was mainly pneumonia (n = 17), interstitial lung disease (n = 5), bronchial asthma (n=3) and others (n = 5). There was statistically significant reduction in respiratory rate (29.40 before Vs 23.50 after; P- <0.0001) and significant improvement in comfort level of the patient after HFNC therapy. Median duration of HFNC was 48 hrs (24-360) hours. Five patients were intubated later on and 4 died in the intensive care unit.

Conclusions: Use of HFNC in patients with persistent ARF was associated with significant and sustained improvement of clinical parameters (respiratory rate). It can be used comfortably for prolonged periods.

References

Kallstrom TJ. AARC clinical practice guideline: oxygen therapy for adults in the acute care facility-2002 revision and update. Respir Care. 2002;47(6):717-20.

Wagstaff TA, Soni N. Performance of six types of oxygen delivery devices at varying respiratory rates. Anaesthesia. 2007;62(5):492-503.

L’Her E, Deye N, Lellouche F, Taille S, Demoule A, Fraticelli A, et al. Physiologic effects of noninvasive ventilation during acute lung injury. Am J Respir Crit Care Med. 2005;172(9):1112-8.

Shoemaker MT, Pierce MR, Yoder BA, DiGeronimo RJ. High flow nasal cannula versus nasal CPAP for neonatal respiratory disease: a retrospective study. J Perinatol. 2007;27:85-91.

Dani C, Pratesi S, Migliori C, Bertini G. High flow nasal cannula therapy as respiratory support in the preterm infant. Pediatr Pulmonol. 2009;44:629-34.

De Klerk A. Humidified high-flow nasal cannula: is it the new and improved CPAP?. Adv Neonatal Care. 2008;8:98-106.

Chanques G, Riboulet F, Molinari N, Carr J, Jung B, Prades A, et al. Comparison of three high flow oxygen therapy delivery devices: a clinical physiological cross-over study. Minerva Anestesiol. 2013;79:1344-55.

Dysart K, Miller TL, Wolfson MR, Shaffer TH. Research in high flow therapy: mechanisms of action. Resp Med. 2009 Oct 1;103(10):1400-5.

Roca O, Riera J, Torres F, Masclans JR. High-flow oxygen therapy in acute respiratory failure. Respir Care. 2010;55:408-13.

Parke R, McGuinness S, Eccleston M. Nasal high-flow therapy delivers low level positive airway pressure. British J Anaesthesia. 2009 Oct 20;103(6):886-90

Sztrymf B, Messika J, Mayot T, Lenglet H, Dreyfuss D, Ricard JD. Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: a prospective observational study. J Crit Care. 2012 Jun 1;27(3):324-e9.

Rello J, Pe´rez M, Roca O, Poulakou G, Souto J, Laborda C, et al. High-flow nasal therapy in adults with severe acute respiratory infection: a cohort study in patients with 2009 influenza A/H1N1v. J Crit Care. 2012;27(5):434-439.

Ou X, Hua Y, Liu J, Gong C, Zhao W. Effect of high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure: a meta-analysis of randomized controlled trials. CMAJ. 2017;189(7):E260-7.

Downloads

Published

2019-03-25

Issue

Section

Original Research Articles